Lynda Polgreen
Pediatric Endocrinology · Orange, CANPI 1679617930
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 69.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $47,782 and has fallen 91.3% since, to $4,157 in 2025. Among pediatric endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $1475.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$116K
- Sanofi-aventis U.S. LLC$27K
- Sanofi$23K
- Eli Lilly$550
- Pfizer$526
- Corcept Therapeutics$82
- plus $200 from 6 others
Across 531 payments — averaging $8136.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$2.4M
- AbbVie$1.3M
- Pfizer$465K
- Takeda Pharmaceuticals U.S.A., Inc.$110K
- Amgen$52K
- Therachon Holding GmbH$16K
- plus $4K from 1 others
What the payments were for
- Consulting fees$53,82232%
- Speaking & faculty fees$88,10553%
- Travel & lodging$18,24411%
- Food & beverage$1,9391%
- Education$4,6393%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 78 | $115,904 |
| Sanofi-aventis U.S. LLC | 7 | $26,626 |
| Sanofi | 12 | $22,861 |
| Eli Lilly | 1 | $550 |
| Pfizer | 2 | $526 |
| Corcept Therapeutics | 5 | $82 |
| Lilly USA, LLC | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| AstraZeneca | 1 | $31 |
| Medtronic | 1 | $29 |
| Eton Pharmaceuticals, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALDURAZYME$29,140
- VOXZOGO 1.2mg$16,714
- VOXZOGO$9,335
- DISEASE STATE$8,541
- NO PRODUCT DISCUSSED$7,368
- Vimizim$2,833
- Naglazyme$2,833
How this compares
$166,748 in reported general payments places this provider in the 95th percentile of 168 pediatric endocrinology providers in California.
Other pediatric endocrinology in Orange
- Timothy FlanneryOrange$32K
- Himala KashmiriOrange$5K
- Daina DreimaneOrange$3K
- Nikita ForghaniOrange$3K
- Lien TrinhOrange$3K
- Gnanagurdasan PrakasamSacramento$805K
- Swati ElchuriVentura$210K
- Karen KleinSan Diego$195K
- Francine KaufmanLos Angeles$184K
- Kevin KaisermanWest Covina$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.